NCT00814931View on ClinicalTrials.gov

Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
StressAnxiety
Interventions
DRUG

CXB722

900 mg CXB722 oral liquid suspension twice a day for 8 days

DRUG

Placebo

matching oral liquid suspension placebo twice a day for 8 days

Trial Locations (1)

33612

University of South Florida, Tampa

Sponsors
All Listed Sponsors
lead

CeNeRx BioPharma Inc.

INDUSTRY

NCT00814931 - Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males | Biotech Hunter | Biotech Hunter